Full Press Release Details
IceCure Receives Notice of Patent Allowance
in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes
IceCure has 20+ patents in the U.S. and the
Company anticipates further market traction upon FDA's marketing authorization decision in early-stage breast cancer
CAESAREA, Israel, June 9, 2025 - IceCure Medical Ltd.
(Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation
technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance
from the United States Patent and Trademark Office for its patent application titled "Cryogen Flow Control". Once granted,
the patent will be in effect until 2045. A patent has already been granted for this invention in Japan and is pending approval in European
Union and other major markets.
"This invention is designed to further improve cryoablation's
efficiency and to expand the number of indications we can deliver in the future," stated Eyal Shamir, IceCure's Chief Executive
Officer. "As we await the U.S. Food and Drug Administration's ("FDA") decision on marketing approval for ProSense
in early-stage breast cancer when combined with adjuvant endocrine therapy for women aged 70 and over, expanding our intellectual property
assets around our platform cryoablation technology is more important than ever. We believe IceCure is the global leader in liquid nitrogen-based
cryoablation technology as we continue to innovate and roll out our systems commercially."
Precise temperature control is crucial for efficacy and tissue safety
in cryoablation procedures. Cryogenic flow control, as covered in this patent, achieves this by utilizing sensor data to regulate the
flow of cryogens, ensuring the desired temperature is reached and maintained at the distal tip of catheters and probes. This optimized
cryogenic delivery enhances treatment effectiveness in cryoablation procedures. Advanced cryogen flow control systems may also offer functionalities,
such as navigation and mapping support within the patient's anatomy, and be incorporated into a wide range of cryosurgical tools.
The ProSense Cryoablation System
provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid
nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney,
ProSense enhances patient and
provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid
nitrogen utilization, ProSense opens that door to fast and convenient office-based procedures for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets
advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense
system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking
statements in this press release when it discusses: the prospective grant of its patent application titled "Cryogen Flow Control";
the prospective effective period of the prospective patent should it be granted; the purposes of the underlying invention; the FDA's
prospective decision on marketing approval for ProSense in early-stage breast cancer; the belief that the Company is the global leader
in liquid nitrogen-based cryoablation technology; and the potential benefits and uses of advanced cryogen flow control systems. Historical
results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials
will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions
to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level
of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's
ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's
ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect
the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals
about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those
factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31,
2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the
SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after
the date of this release, except as required by law.